Print Page  Close Window

2018 News Releases

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006
DateTitle  
10/15/18Emergent BioSolutions Completes Acquisition of Adapt Pharma and Flagship Product Narcan® (Naloxone HCI) Nasal SprayDownload PDFPrinter Friendly Version
10/11/18Emergent BioSolutions to Release Third Quarter 2018 Financial Results and Conduct a Conference Call on November 1, 2018Download PDFPrinter Friendly Version
10/04/18Emergent BioSolutions Completes Acquisition of Specialty Vaccines Company PaxVax Printer Friendly Version
08/28/18Emergent BioSolutions Joins Effort to Combat National Public Health Threat From Opioid Overdose Through Acquisition of Adapt Pharma and Its Flagship Product NARCAN® (naloxone HCl) Nasal SprayDownload PDFPrinter Friendly Version
08/17/18Emergent BioSolutions to Participate in Series of Near-Term Investor ConferencesDownload PDFPrinter Friendly Version
08/16/18CEPI Awards Contract Worth up to $36 million to Profectus BioSciences and Emergent BioSolutions to Develop Lassa Virus VaccineDownload PDFPrinter Friendly Version
08/09/18Emergent BioSolutions to Acquire Specialty Vaccines Company PaxVaxDownload PDFPrinter Friendly Version
08/02/18Emergent BioSolutions Reports Financial Results for Second Quarter and Six Months of 2018Download PDFPrinter Friendly Version
07/31/18Emergent BioSolutions Initiates Phase 1 Clinical Study of Zika Virus Immune Globulin TherapeuticDownload PDFPrinter Friendly Version
07/18/18Emergent BioSolutions to Release Second Quarter 2018 Financial Results and Conduct a Conference Call on August 2, 2018Download PDFPrinter Friendly Version
06/08/18Emergent BioSolutions to Participate in the Goldman Sachs 39th Annual Global Healthcare ConferenceDownload PDFPrinter Friendly Version
06/07/18Emergent BioSolutions Announces $50 Million Expansion of Baltimore Fill/Finish FacilityDownload PDFPrinter Friendly Version
05/24/18CEPI Awards $25 Million Contract to Profectus BioSciences and Emergent BioSolutions to Develop Nipah Virus VaccineDownload PDFPrinter Friendly Version
05/10/18Emergent BioSolutions to Hold Annual Meeting of Stockholders on Thursday, May 24, 2018 at 9:00 AM EDT; Webcast Will Be AvailableDownload PDFPrinter Friendly Version
05/03/18Emergent BioSolutions Reports First Quarter 2018 Financial ResultsDownload PDFPrinter Friendly Version
04/19/18Emergent BioSolutions to Release First Quarter 2018 Financial Results and Conduct a Conference Call on May 3, 2018 Printer Friendly Version
04/12/18Emergent BioSolutions Announces Successful Completion of Mutual Recognition Procedure for Market Authorization of BioThrax in European CountriesDownload PDFPrinter Friendly Version
03/26/18Emergent BioSolutions Announces Executive Management Changes That Enhance Execution of Company’s Growth StrategyDownload PDFPrinter Friendly Version
03/22/18Emergent BioSolutions to Implement Stock Repurchase Program for up to $50 Million of Its Common StockDownload PDFPrinter Friendly Version
02/28/18Emergent BioSolutions Awarded One-Year CDC Contract Valued at $26 Million for Vaccinia Immune Globulin ProgramDownload PDFPrinter Friendly Version
02/26/18Emergent BioSolutions and Valneva Initiate Phase 1 Clinical Study to Evaluate Vaccine Candidate Against Zika VirusDownload PDFPrinter Friendly Version
02/22/18Emergent BioSolutions Reports Fourth Quarter and Twelve Months 2017 Financial ResultsDownload PDFPrinter Friendly Version
02/08/18Emergent BioSolutions to Release Fourth Quarter and Full Year 2017 Financial Results and Conduct a Conference Call on February 22, 2018Download PDFPrinter Friendly Version
01/08/18Emergent BioSolutions Announces Preliminary 2017 Financial Results and Provides 2018 Financial OutlookDownload PDFPrinter Friendly Version
01/04/18Emergent BioSolutions Initiates Phase 2 Clinical Study to Evaluate FLU-IGIV to Treat Serious Influenza A InfectionDownload PDFPrinter Friendly Version
01/03/18Emergent BioSolutions to Participate in First Quarter 2018 Investor ConferencesDownload PDFPrinter Friendly Version